Skip to main content
. 2022 Aug 1;33(8):696–703. doi: 10.5152/tjg.2022.21829

Figure 3.

Figure 3.

Progression-free survival (PFS) and overall survival (OS) of the high let-7c and let-7d Gem + Cape and FOLFIRINOX arms with pancreatic cancer of tail origin. Gem + Cape, gemcitabine + capecitabine.